In a letter addressed to the Food and Drugs Authority (FDA), Samospharma Limited has vehemently denied any association with Aveo Pharmaceutical Pvt. Ltd, and Westfin Pharmaceutical Pvt. Ltd, two companies mentioned in a recent BBC report relating to the sale of opioid pills in West Africa.
Samospharma, in a letter dated February 25, 2025, and signed by its Managing Director
Eugene Boakye refutes claims made by the FDA, which suggested that Samospharma was linked to Aveo Pharmaceutical Pvt. Ltd and Westfin Pharmaceutical Pvt. Ltd. Samospharma expressed deep concern over what it describes as “baseless and damaging” allegations.
The company has called on the FDA to provide evidence supporting these claims and to issue a public correction to clear its name. Additionally, Samospharma has demanded a thorough internal review of the FDA’s processes to prevent such errors in the future.
The company stated, “We do not, and never have, engaged in any fraudulent practices as alleged in the BBC report, nor do we associate with entities that do such as Aveo Pharmaceutical Pvt. Ltd, and Westfin Pharmaceutical Pvt. Ltd.”
Samospharma emphasized its commitment to maintaining the highest standards of ethics, compliance, and legal integrity in all its operations.
In addition to refuting the allegations of association with Aveo and Westfin, Samospharma has also pointed out a significant error in the FDA’s letter. The letter incorrectly stated that Indiana Ophthalmics LLP is the manufacturer of Timonidin Eye Drops, a product approved by the FDA. Samospharma has clarified that this statement is inaccurate, as Timonidin Eye Drops are not manufactured by Indiana Ophthalmics LLP.
While Indiana Ophthalmics LLP is a respected and duly registered ophthalmic company in India, Samospharma has stated that it has never been the manufacturer of Timonidin Eye Drops. The company has urged the FDA to review its internal records and promptly correct this misrepresentation.
To substantiate its claims, Samospharma attached several documents to its letter, including:
Response from Kilitch Drugs (India) Ltd: The manufacturers and exporters of Timonidin Eye Drops and Samocef Injection have confirmed their role in the production and export of these products.
Commercial Invoices and FDA Consignment Documents: These documents provide evidence of the importation of Timonidin Eye Drops and Samocef Injection in 2022 and 2023.
Export Invoice and Bill of Entry: Samospharma has also provided an export invoice from Sudarshan Pharma Industries Ltd and a Bill of Entry from the GRA Customs Division for the importation of Prolatan (Latanoprost) Eye Drops in 2023.
These documents are intended to demonstrate that Samospharma has been transparent in its dealings and has complied with all regulatory requirements in the importation and distribution of pharmaceutical products in Ghana.
“We trust that the FDA, as a reputable regulatory body responsible for upholding integrity and factual accuracy, will act expeditiously and responsibly in resolving this grave misrepresentation,” said Samospharma.
Samospharma has also emphasized its commitment to fostering a cordial working relationship with the FDA to ensure the continued delivery of quality pharmaceutical products to the Ghanaian public.
